MIDLAND, Texas, Aug. 12, 2025 /PRNewswire/ -- Dawson Geophysical Company (NASDAQ: DWSN) (the "Company") today reported unaudited financial results for its second quarter ended June 30, 2025.Management CommentTony Clark, Dawson's President and CEO, commented, "Due to the observed increase in demand for large integrated high-resolution, high channel count surveys and improvement to our backlog, we made the decision to make a significant capital investment to purchase new single node channels from a wholly-own ...

  Vancouver, BC, August 12, 2025 – TheNewswire - Silver North Resources Ltd. (TSX-V: SNAG, OTCQB: TARSF) “Silver North” or the “Company”) announces that the non-brokered private placement (the “Offering”) announced June 23, 2025 has now closed.  “With the closing of this offering, Silver North is now able to continue to unlock value at the Haldane Property in the historic Keno Hill Silver District,” stated Jason Weber, P.Geo., President and CEO of Silver North. “Our 2025 program at Haldane will commence im ...

FORT COLLINS, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ: WWD), a global leader in energy controls for aerospace and industrial markets, today announced key leadership changes aligned with the company’s continued focus on growth, innovation, and operational excellence. These changes will take effect on October 1, 2025. Shawn McLevige has been appointed President of Woodward’s Aerospace Segment. In this role, Shawn will report directly to Chip Blankenship, Chairman and CEO, as a member o ...

WILMINGTON, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Live Oak Bancshares announced today the appointment of Jeffrey W. Lunsford to its board of directors. Lunsford has also been appointed to the board of directors of Live Oak Bank. “As a successful entrepreneur and financial technology expert, Jeff brings a deep level of technical expertise to our board,” said Live Oak Bancshares Chairman and CEO James S. (Chip) Mahan III. “His skill sets are an excellent match for Live Oak as we continue to redefine what it ...

ATHENS, Greece, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (together with its subsidiaries, unless context otherwise dictates, “OET” or the “Company”) (NYSE: ECO, OSE: OET) today reported its unaudited condensed financial results for the second quarter and six-month period of 2025, which are attached to this press release. Financial performance of the Second Quarter Ended June 30, 2025 Revenues of $93.9 million in Q2 2025, compared to $112.0 million in Q2 2024.Profit of $26.9 million in Q2 ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Customers arrive at a Cava restaurant in New York City on June 22, 2023.Cava on Tuesday lowered its full-year forecast for same-store sales growth after a disappointing second quarter.For the full year, Cava now anticipates same-store sales growth of 4% to 6%, down from its prior range of 6% to 8%.Shares of the company plunged 20% in extended trading. The stock has fallen 40% this year, including the after-hours move.Here's what the company reported compared with what Wall Street was expecting, based on a s ...

DELRAY BEACH, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced that its Chief Executive Officer, Sandra Campos, and Chief Financial Officer, Robyn D’Elia, have resigned from their positions and employment with the Company. As part of the leadership changes, Leslie C.G. Campbell, the Chair of the Company’s Board of Directors (the “Board”), has assumed the role of Interim Chief Executive Officer, and Douglas ...

Monday.com Ltd. MNDY reported a rise in sales for the second quarter on Monday.The software company posted revenue of $299 million, up 27% year over year, driven by strong demand from enterprise customers and growth in its customer base. The company also added a record number of net new customers generating over $100,000 in annual recurring revenue (ARR), while its monday CRM product reached $100 million in ARR just three years after launch.Looking ahead, Monday.com expects third-quarter revenue of $311 mil ...

Core Insights - Solid Biosciences is advancing its pipeline with three clinical-stage programs targeting neuromuscular and cardiac diseases, including SGT-003 for Duchenne Muscular Dystrophy, SGT-212 for Friedreich's Ataxia, and SGT-501 for Catecholaminergic Polymorphic Ventricular Tachycardia [2][4][9] Clinical Trials and Pipeline - The Phase 1/2 INSPIRE DUCHENNE trial has dosed 15 participants, with ongoing recruitment and no serious adverse events reported [1][3][5] - SGT-212 and SGT-501 are expected to initiate Phase 1b trials in Q4 2025, with SGT-212 being the first gene therapy for Friedreich's Ataxia utilizing a dual route of administration [1][4][6][9] - A randomized, double-blind, placebo-controlled trial for SGT-003 is planned outside the U.S. in Q4 2025 to support global regulatory authorizations [5] Financial Position - As of June 30, 2025, the company reported $268.1 million in cash and equivalents, providing a cash runway into H1 2027 [1][8] - Research and Development expenses for Q2 2025 were $32.4 million, up from $19.5 million in Q2 2024, primarily due to increased costs associated with SGT-003 [8][13] - The net loss for Q2 2025 was $39.5 million, compared to $25.1 million in Q2 2024, reflecting increased operational expenses [13][15] Strategic Partnerships and Technology - Solid has executed over 25 agreements for the use of its proprietary AAV-SLB101 capsid with academic labs and institutions [1][9] - The company is developing multiple next-generation capsid and promoter libraries, with the first cardiac capsid library selection expected in Q4 2025 [9] Market Position and Mission - Solid Biosciences is focused on improving the lives of patients with rare diseases, leveraging its expertise in genetic medicine to innovate therapies for conditions like Duchenne and Friedreich's Ataxia [2][11]